Mary Ann Anderson

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy

Shuo Ma, John F Seymour, Danielle M Brander, Thomas J Kipps, Michael Y Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W Roberts

Journal article  |  2021  |  BLOOD

We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocyt..

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.

Thomas E Lew, Victor S Lin, Edward Robert Scheffer Cliff, Piers Blombery, Ella R Thompson, Sasanka Mithila Handunnetti, David A Westerman, Bryone Jean Kuss, Constantine S Tam, David Ching Siang Huang, John F Seymour, Andrew W Roberts, Mary Ann Anderson

Journal article  |  2021  |  Blood Adv

Covalent Bruton tyrosine kinase inhibitors (BTKis) and the BCL2 inhibitor venetoclax have significantly improved outcomes for pati..

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.

Piers Blombery, Thomas E Lew, Michael A Dengler, Ella R Thompson, Victor S Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka Mithila Handunnetti, Dennis Carney, David A Westerman, Constantine S Tam, Jerry M Adams, Andrew H Wei, David Ching Siang Huang, John F Seymour, Andrew Roberts, Mary Ann Anderson

Journal article  |  2021  |  Blood

The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. ..

Review of Venetoclax in CLL, AML and Multiple Myeloma.

Masa Lasica, Mary Ann Anderson

Journal article  |  2021  |  J Pers Med

Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic poten..

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

Sasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, Matthew S Davids, Shuo Ma, Michelle Boyer, Jennifer Arzt, Abdullah Al Masud, Relja Popovic, Amanda Jacobson, Su Y Kim, John F Seymour

Journal article  |  2021  |  eJHaem

Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.

EJ Leitinger, RM Wright, N Nelson, MA Anderson, S Juneja

Journal article  |  2021  |  Pathology

CAR-T cell therapy: practical guide to routine laboratory monitoring

Adrian G Selim, Adrian Minson, Piers Blombery, Michael Dickinson, Simon J Harrison, Mary Ann Anderson

Journal article  |  2021  |  PATHOLOGY

Chimeric antigen receptor (CAR)-T cell therapy is a genetically-modified cellular immunotherapy that has a current established rol..

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, Ella R Thompson, Xiangting Chen, Tamia Nguyen, Mary Ann Anderson, David Alan Westerman, John F Seymour, Constantine S Tam, Michael A Dengler, David CS Huang, Andrew Wei, Andrew W Roberts

Journal article  |  2020  |  Blood

Venetoclax (Ven) is an effective element of treatments for chronic lymphocytic leukemia (CLL) with high response rates observed in..

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Joanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W Roberts, John F Seymour, Constantine S Tam, David S Ritchie, Rachel M Koldej

Journal article  |  2020  |  BLOOD ADVANCES

Combination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or..

CLL-088: Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials

Mary Ann Anderson, Matthew S Davids, Arnon P Kater, Tara Cochrane, Fatih Demirkan, Yair Herishanu, Brian Leber, Eugene Nikitin, Abdullah A Masud, Tanya S Rosenberg, Simon Sharmokh, Stan Fort, Francesco Forconi

Journal article  |  2020  |  Clinical Lymphoma Myeloma and Leukemia